OABI - NASDAQ
OmniAb, Inc.
$2.62
-4.6%OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
At a Glance
Live SnapshotOmniAb, Inc. Management Team
Mr. Charles S. Berkman J.D.
Chief Legal Officer & Secretary
Compensation
$695,487
Mr. Kurt A. Gustafson
Executive Vice President of Finance & Chief Financial Officer
Compensation
$677,485
Mr. Matthew W. Foehr
President, Chief Executive Officer & Director
Compensation
$969,332
Ms. Donna Ventura CPA
Senior Vice President & Corporate Controller
Dr. Bill Harriman Ph.D.
Senior Vice President of Antibody Discovery
Dr. Christel Iffland Ph.D.
Senior Vice President of Antibody Technologies
Dr. Yasmina Noubia Abdiche Ph.D.
Senior Vice President of Exploratory Research
Ms. Cia McCaffrey
Vice President of People & Talent
OmniAb, Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.24M and sold $283K worth of OABI shares, resulting in $961K of net buying activity.
3 Months
0
0.00
33.3K
49.64K
-50K
-$50K
3-6 Months
0
0.00
130.0K
233.39K
-233K
-$233K
6-9 Months
77.3K
107.71K
0
0.00
+108K
+$108K
9-12 Months
620.5K
1.14M
0
0.00
+1.1M
+$1.14M
Top Buyers
Foehr Matthew W
Director, Officer: President And Ceo
$1000K
Higgins John L
Director
$108K
Gotwals Philip J
Director
$68K
Crouse Steven C.
Director
$68K
Top Sellers
Foehr Matthew W
Director, Officer: President And Ceo
$143K
Gustafson Kurt A
Officer: Executive Vp, Finance And Cfo
$85K
Berkman Charles S
Officer: Chief Legal Officer
$55K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $961K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
4 insider buyers vs. 3 sellers. More insiders buying than selling indicates positive sentiment.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
OABI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 17, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 17, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 18, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | May 01, 2023 | June 23, 2023 | 2023 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.